Glomerulonephritis
Conditions
Brief summary
The trial is the first human trial. The safety, tolerability, PK and PD of HRS-5965 tablets will be evaluated in healthy subjects and subjects with impaired renal function. The study was divided into three parts: Part 1: single ascending dose, randomized, double-blind study，with 6 dose groups preset, of which 1 group will be administered under fasted and fed conditions; Part 2: Multiple ascending dose, randomized, double-blind study，with 4 dose groups preset; Part 3: an open-label, nonrandomized, single-dose study to evaluate the effect of severe renal impairment (RI) on the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS -5965 compared to demographically-matched healthy participants with normal renal function.
Interventions
DRUGHRS-5965
Subjects took HRS5965 tablets in Part 1, Part 2 and Part 3.
DRUGPlacebo
Subjects took Placebo in Part 1 and Part 2.
Sponsors
Chengdu Suncadia Medicine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Single-dose and multi-dose, dose escalation, placebo-controlled study
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
\- Healthy subjects study 1. Healthy male or female, age ≥ 18 years old and ≤ 70 years old (on the day of signing the informed consent); 2. 18.5kg/m2 ≤BMI\<30 kg/m2, and the weight of men should be ≥ 50kg, and that of women should be ≥ 45kg. Study on subjects with renal insufficiency 1. Age ≥ 18 years old and ≤ 70 years old (on the day of signing the informed consent), both men and women can; 2. 18.5kg/m2≤BMI\<30 kg/m2； 3. The estimated glomerular filtration rate of subjects with chronic renal insufficiency conforms to 15 ≤ EGFR \< 30 ml/min/1.73m2 (calculated according to CKD-EPI formula, see Appendix 2 of the scheme).
Exclusion criteria
\- Healthy subjects study 1. The researcher has determined that there may be diseases or medical conditions that affect the absorption, distribution, metabolism and excretion of drugs or reduce compliance; 2. The estimated glomerular filtration rate conforms to EGFR \< 90 ml/min/1.73m2 (calculated according to CKD-EPI formula, see Appendix 2 of the scheme); 3. According to the judgment of the researcher, any physiological or psychological disease or condition that may increase the risk of the test, affect the subject's compliance with the protocol, or affect the subject's completion of the test. Study on subjects with renal insufficiency 1. Those who received renal replacement therapy within 12 weeks before screening; Or the two tests in the screening period indicate that the renal function is unstable (the results in the screening period meet the diagnostic criteria of 2012 KDIGO acute renal injury, or the changes that do not meet the above criteria but are judged to be clinically significant by the researcher. If there are reasonable reasons, the third test is allowed, and the interval between two consecutive tests should be more than 3 days but not more than 7 days); 2. According to the judgment of the researcher, the subject has any of the following: in the state of progression or prognosis of disease (including primary renal disease, complications and other complications); The treatment plan needs to be adjusted at any time; Any physical or mental disease or condition that may increase the risk of the test, affect the subject's compliance with the protocol, or affect the subject's completion of the test.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence and severity of adverse events to assess safety and tolerability | up to 24 days |
Secondary
| Measure | Time frame |
|---|---|
| Peak plasma concentration (Cmax) on Day 1 for Part 1 and Part 3 | Pre-dose to 144 hours post-dose |
| Time to maximum plasma concentration (Tmax) on Day 1 for Part 1 and Part 3 | Pre-dose to 144 hours post-dose |
| Area under the plasma concentration versus time curve (AUC) on Day 1 for Part 1 and Part 3 | Pre-dose to 144 hours post-dose |
| Peak plasma concentration (Cmax) on Day 1 and Day 10 for Part 2 | Pre-dose to 144 hours post-dose |
| Time to maximum plasma concentration (Tmax) on Day 1 and Day 10 for Part 2 | Pre-dose to 144 hours post-dose |
| • Area under the plasma concentration versus time curve (AUC) on Day 1 and Day 10 for Part 2 | Pre-dose to 144 hours post-dose |
Countries
China
Outcome results
None listed